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Synopsis 
This thesis entitled “Polymorphism and Solubility of Selected Active 
Pharmaceutical Ingredients” consists of seven chapters. 
CHAPTER ONE 
Introduction 
Chemistry is an evolving subject and it is traditionally divided into four 
categories as organic, inorganic, physical and analytical chemistry. A new 
classification in the modern era is the (supramolecular) solid state chemistry 
which is different from the molecular chemistry (liquids and gases). It has now 
reached the immense importance in the level of identification, separation and 
characterization of different crystalline forms of the same molecule or of 
aggregates of molecules with other molecules due to the difference in their 
physical and chemical properties. Physical properties are an intrinsic part of solid 
state chemistry since the broad area of structure-property relationship needs the 
identification of new solid crystalline forms such as polymorphs, 
solvates/hydrates, salts and cocrystals (Figure 1) and their characterization to 
understand their properties to control their activity. The importance of identifying 
these crystalline materials is to investigate their physico-chemical issues of active 
pharmaceutical ingredients (APIs) and address the solubility, stability and 
hydration problems using the crystal engineering approach. Crystal engineering 
of APIs through cocrystallization has gained an immense interest among the 
academicians, pharmaceutical scientists and US-FDA regulating as means of 
optimizing the physical properties and/or stability of solid dosage forms.  
McCrone defined the term polymorphism as “a solid crystalline phase of 
a given compound resulting from the possibility of at least two different 
crystalline arrangements of the molecules of that compound in the solid state”. It 
can be classified as conformational polymorph (due to flexible rotation of 
molecule), synthon polymorph (due to difference in hydrogen bonding patterns) 
and packing polymorph (because of changes in the crystal packing of molecules) 
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in 2D or 3D. The term Pharmaceutical Cocrystal can be defined as “the 
crystalline complex of two or more neutral molecules is constituted including 
API, bonding together in the crystal lattice through non-covalent interactions 
such as hydrogen bonding”. Polymorphism and Cocrystallization has great 
importance in pharmaceutical industry, dyes and pigment, agrochemicals, 
explosive materials etc. due to its ability to alter the melting point, color, 
compressibility, filterability, stability, solubility etc. of the challenging solid 
materials. Salt formation is an acid base reaction and a compound having an 
acidic or basic group can crystallize in salt preparation in solution 
crystallizations. The traditional approach of salt formulation to improve drug 
solubility is unsuccessful with the molecules that lack of ionisable functional 
groups, have sensitive moieties that are prone to decomposition/ racemisation 
and/or are not sufficiently acidic /basic to enable salt formation. 
      Amorphous                                 Solid Crystalline       Single Component 
  
      
       Eutectic Mixture/              Multi Component    
       Solid Solution 
 
 
                    Cocrystals/Hydrates/Solvates/Salts                Polymorphs 
 
Figure 1 Various solid forms based on structure and composition variations. 
 
Solubility is one of the most important physicochemical properties when 
evaluating compounds as potential drug candidates. The thermodynamic 
solubility of a compound in a solvent is the maximum amount of the most stable 
crystalline form of the compound that can remain in solution under equilibrium 
conditions. Kinetics is a time-dependent phenomenon, and thermodynamics is, by 
definition, time independent. Poor aqueous solubility of any drug is likely to 
result in poor absorption, even if the permeation rate is high, since the flux of a 
drug across the intestinal membrane is proportional to the concentration gradient 
between the intestinal lumen and the blood. Again high concentrations of poorly 
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soluble drugs in organisms may result in crystallization and acute toxicity. There 
is need to balance between solubility and dosage form of a drug. Overall, poor 
solubility of drug candidates has been identified as the main cause of numerous 
drug development failures at the final stages of formulations. We addressed these 
issues in some of the active compounds by correlating the differences in 
conformation, changes in functional groups in polymorphs and this study 
provides a guide in drug delivery for solubility optimization. In this thesis, we 
have chosen few drugs or biologically active compounds to study their 
polymorphic behaviours and cocrystal/salt formation using high throughput 
screening and highlighted their solubility and stability differences with respect to 
the structure modifications such as cocrystals and salt formation. 
CHAPTER TWO 
Polymorphism in Cardiosulfa and Its Analogs   
Cardiosulfa is a biologically active sulfonamide molecule which induces 
abnormal heart development in zebrafish embryo through activation of the aryl 
hydrocarbon receptor (AhR). The present report is a systematic study of 
polymorphic search of cardiosulfa (more active) and its biologically active 
analogs (moderate and less active) belong to the N-(9-ethyl-9H-carbazol-3-
yl)benzene sulfonamide skeleton (Scheme 1). Cardiosulfa (molecule 1, R1 = NO2, 
R2 = H, R3 = CF3), molecule 2 (H, H, CF3), molecule 3 (CF3, H, H), molecule 4 
(NO2, H, H), molecule 5 (H, CF3, H), and molecule 6 (H, H, H) were synthesized 
and subjected to a polymorph search and solid state characterization by X-ray 
diffraction, DSC, VT-PXRD, FT-IR and ss-NMR. Molecule 1 was obtained in a 
single crystalline modification which is sustained by N−H···π and C−H···O 
interactions, but devoid of strong intermolecular N−H···O hydrogen bonds. 
Molecule 2 showed a N−H···O catemer C(4) chain in Form I whereas a second 
polymorph was characterized by PXRD. The dimorphs of molecule 3 contain 
N−H···π and C−H···O interactions but no N−H···O H bonds. Molecule 4 is 
trimorphic with N−H···O catemer in Form I, and N−H···π and C−H···O 
interactions in Form II, and a third polymorph was characterized by PXRD. Both 
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polymorphs of molecule 5 contain the N−H···O catemer C(4) chain, whereas the 
sulfonamide N−H···O dimer synthon R2
2
(8) was observed in polymorphs of 6. 
Differences in the strong and weak hydrogen bond motifs were correlated with 
the substituent groups and the solubility and dissolution rates with the 
conformation in the crystal structure of 1-6 (Figure 2). Higher solubility 
compounds, such as 2 (10.5 mg/mL) and 5 (4.4 mg/mL), adopt a twisted 
confirmation whereas less soluble 1 (0.9 mg/mL) is nearly planar. This study 
provides practical guides for functional group modification of drug lead 
compounds for solubility optimization.  
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Scheme 1 Molecular structures of Cardiosulfa and its analogs. 
 
 
 
 
(a) (b) 
Figure 2 (a) Dissolution profiles of sulfonamides 1-6 in 80% ethanol–water 
mixture at 37 °C. (b) Overlay of molecular conformations of molecules 1-6.  
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CHAPTER THREE 
Structure-property Comparison of Neutral and Zwitterionic Polymorphs 
Several amphoteric model compounds and drugs, such as isomers of 
aminobenzoic acids (ortho, meta, and para), N-aryl-2-amino-nicotinic acids (three 
isomers), drugs such as aminosalicylic acids (meta and para), clonixin, and 
niflumic acid were selected to obtain their reported zwitterionic and neutral 
polymorphs (Scheme 2) with the objective to correlate their X-ray crystal 
structures with solubility and dissolution rate, and stability. We were successful 
in crystallizing neutral and ionic polymorphs for 2- and 3-aminobenzoic acid 
(ABA), 2-(p-tolylamino)nicotinic acid (TNA), and clonixin (CLX), as well as 4- 
and 5-aminosalicylic acid (4-ASA as neutral and 5-ASA in ionic form). The 
neutral and zwitterionic crystalline polymorphs were differentiated by their 
distinctive powder XRD, FT-IR, Raman and ss-NMR spectroscopy, and further 
quantified by Hirshfeld surface analysis. Phase transitions were monitored by 
DSC and VT-PXRD. The difference in solubility and dissolution rates of the 
neutral and zwitterionic polymorphs were correlated with their hydrogen 
bonding, see Figure 3a-c, (O–H···O, O–H···N and N+–H···O–). The faster 
dissolution rates of the ionic forms were ascribed to stronger, attractive 
interactions between the solvent molecules and the zwitterionic functional groups 
(Figure 3d). Even as there is no general strategy yet to crystallize ionic 
polymorphs of amphoteric molecules, the present study shows the advantages of 
zwitterionic forms for solubility enhancement.  
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Scheme 2 Neutral and Zwitterionic crystal structures in CSD (Feb 2014 update). 
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Figure 3 Clonixin polymorphs. (a) Strong acid–pyridine O–H···N synthon in 
neutral form I (a), acid dimer O–H···O R2
2
(8) motif in neutral form III (b), acid–
pyridine ionic N
+–H···O–H bond in zwitterionic form II (c), Dissolution profile 
of CLX polymorphs in 60% EtOH–water. 
CHAPTER FOUR 
Conformational Polymorphs of N-Acetyl-L-cysteine 
A novel polymorph of N-acetyl-L-cysteine (NAC) is identified after three 
decades of the first report on the X-ray crystal structure of this bioactive 
compound. The crystal structure of the new orthorhombic polymorph (form II in 
P212121 space group) is characterized by X-ray diffraction compared to the 
triclinic structure of form I (NALCYS02 and NALCYS10 in P1 space group). 
Both polymorphs contain a C(7) chain of COOH···O=C-CH3 hydrogen bonds 
except that the COOH group is rotated by 180º in form II to make an auxiliary C–
H···O interaction with the methyl group in a R2
2
(8) ring motif. The known form I 
contains weak S–H···O=C-OH and N–H···S hydrogen bonds whereas the new 
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form II has only N–H···S interaction (Figure 4). The conformational polymorphs 
of NAC were compared by Hirshfeld surface analysis (dnorm) and XPac methods, 
and spectroscopically characterized by FT-IR and Raman. The bulk phases were 
distinguished by their 
13
C ss-NMR and powder X-ray diffraction line patterns. 
The two polymorphs are enantiotropically related (form I has higher melting 
temperature and lower enthalpy of fusion). However, no phase transition was 
observed in DSC. The metastable form II converted to stable form I in solid-state 
grinding, slurry medium, and storage in ambient conditions for 3 months.  
 
 
(a) (b) 
Figure 4 NAC polymorphs (a) 2D network of S−H···O and O−H···O hydrogen 
bonds in form I. (b) C−H···O hydrogen bonds (red dots) and S−H···S short 
contacts (blue dots) in form II. 
CHAPTER FIVE 
Pharmaceutical Cocrystals of Voriconazole  
Voriconazole ((2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-
1-(lH-l,2,4-triazol-l-yl)butan-2-ol, VZL) is an antifungal drug with low aqueous 
solubility of 0.71 mg/mL and it is a BCS class II drug (Biopharmaceutics 
Classification System) of the azole family. We have prepared a nitrate salt and 
three cocrystals of VZL with p-hydroxybenzoic acid, p-aminobenzoic acid (both 
are GRAS compounds) and m-nitrobenzoic acid coformers (Scheme 3) to 
improve aqueous solubility and stability. All the four multi-component crystals of 
voriconazole were obtained by solution crystallization as well as solid-state 
grinding and their structures were confirmed by X-ray diffraction, FT-IR, Raman, 
and NMR spectroscopy, and thermal techniques. VZL–PHBA and VZL–PABA 
are 3D isostructural by XPac calculations and molecular packing arrangement. A 
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notable result from a crystal engineering viewpoint is that the supramolecular 
synthon between the basic drug and the acidic coformer undergoes a switch based 
on the pKa of the acid. The solubility of Voriconazole-nitrate salt is 10 times 
higher soluble than the API in acidic medium (0.1 N HCl), see Figure 5. 
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Scheme 3 Voriconazole and its successful coformers in cocrystallization method. 
 
Figure 5 Dissolution profile of voriconazole pure base and its solid forms in 
0.1N HCl solution in 4 h at 37 ºC. 
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CHAPTER SIX 
Pharmaceutical Salts of Active Compounds 
Almost half of the drugs are marketed as salts and reported as they have 
improved the performance of drug product in clinical usage. This is well 
established solid formulation in pharmaceutical field in respect to improving drug 
properties of BCS class II using cocrystallization technique. Gliclazide (GLZ), 
Clonixin (CLX) and Clofibric acid (CLF) are the low aqueous soluble drugs 
selected for salt screening experiments in an attempt to improve their solubility 
(Scheme 4).   
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Scheme 4 Molecular structures of selected APIs for salt screen. 
Gliclazide (GLZ) N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-
4-methylbenzene- sulfonamide, is a second-generation sulphonylurea drug used 
in the treatment of type II diabetes. Gliclazide is categorised in BCS II 
classification as it is a low aqueous soluble drug. Hence, it was crystallized with 
sodium hydroxide and other bases in EtOH solvent to improve the solubility 
during our attempt to design novel salts of sulfonylurea functional group. A new 
solid form of sodium gliclazate (GLZ-Na) is crystallized in P21/c space group 
that was also confirmed by DSC and PXRD. Both the solid forms are 
characterized by 
13
C ss-NMR spectroscopy. As expected, the solubility (19.6 
mg/mL) is 10 times higher and faster dissolution rate (1.0 mg/cm
2
/min) observed 
for GLZ-Na salt than the reference drug GLZ (2.2 mg/mL, 0.32 mg/cm
2
/min) in 
50% EtOH-water mixture (Figure 6.1).  
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Figure 6.1Dissolution profile of GLZ and GLZ-Na in 50% EtOH-water mixture 
at 37 ºC. 
Clonixin, 2-[(3-chloro-2-methylphenyl)amino]-3-pyridinecarboxylic acid 
is a non-steroid analgesic drug. Clonixin (CLX), 2-[(3-chloro-2-
methylphenyl)amino]-3-pyridinecarboxylic acid It belongs to the fenamate group 
and although structurally similar to mefenamic acid it is more potent as an 
analgesic than as an anti-inflammatory, suggesting that clonixin may act on the 
central nervous system. The piperazinum-clonixate (CLX-PIP) and cytosinium-
clonixate salts (CLX-CYT) were the successful solid forms obtained after many 
trials in solution crystallization and further confirmed by single crystal and 
powder X-ray diffraction methods. The stacking of CLX molecules are sustained 
by the N
+–H···O– (1.59 Å, 173º and 2.53Å, 127º) and N+–H···N (1.92 Å, 158º) 
hydrogen bonding networks with ionized piperazine (Figure 6.2a).  Two 
molecules of CLX are interacting through the N
+–H···O– (1.68 Å, 172º) and C–
H···N (2.69 Å, 106º) interactions with cytosinium ions in CLX-CYT. Both salts 
showed significant differences in solid state NMR and DSC analysis with respect 
to the CLX. These organic salts exhibit high solubility (CLX-PIP, 21.8 mg/mL; 
CLX-CYT, 14.1 mg/mL) and dissolution rate (0.47 mg/cm
2
/min, 0.40 
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mg/cm
2
/min) than the clonixin drug (1.9 mg/mL, 0.14 mg/cm
2
/min). Two salts 
are found to more soluble than the stable zwitterionic form (2.0 mg/mL, 0.20 
mg/cm
2
/min) of CLX (Fig 6.3).  
 
 
 
(a) (b) 
Figure 6.2 (a) N–H···O and N–H···N interaction in CLX-PIP (b) N–H···O and C–H···N 
interactions in CLX-CYT. 
 
 
Figure 6.3 Dissolution profiles of CLX and CLX-PIP and CLX-CYT salts in 
60% EtOH-water mixture at 37 ºC. 
Clofibric acid (CLF), 2-(4-Chlorophenoxy)-2-methylpropanoic acid, is an 
antihyperlipidemic drug; pharmaceutically active metabolite of lipid regulators 
fibrates and the recent literature indicate that clofibric acid produces potent 
antitumor effects against ovarian cancer in conjunction with a reduction of 
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angiogenesis and induction of apoptosis (fibrate; fenofibrate). GRAS molecules 
as the coformers such as Piperazine, Cytosine etc. were used to obtain new salt 
solid forms of CLF using the solution crystallization techniques. Piperazinium-
clofibrate (CLF-PIP) salt and Cytosinium-clofibrate-cytosine monohydrate (CLF-
CYT) confirmed by only single crystal XRD and refined in P21/n and C2 space 
groups respectively. The CLF molecule is interacting with piperazine molecule 
via two strong hydrogen bond N
+–H···O– (1.68Å, 176º, 1.72 Å, 163º) and one 
N
+–H···O– weak hydrogen bonds (2.53Å, 119º) in CLF-PIP (Figure 6.4a). In case 
of CLF-CYT, two neutral cytosine molecules are interacting via two point N–
H···O synthon (1.84 Å, 169º) where as the ionic cytosine were connected by two 
point ionic synthon N
+–H···O– (1.81Å, 174º) interactions. The neutral cytosine is 
connected directly to two different clofibric acid molecules by only N1–H1···O2 
(1.83Å, 174º) and N3–H3B···O3 (2.01Å, 159º) interactions. The weak hydrogen 
bonds O6–H6B···O3 (1.84Å, 161º) and O6–H6C···O2 (2.12Å, 136º) is 
connecting the water molecules with CLF and the N4–H4B···O6 (1.93Å, 160º) 
interactions is bound by cytosinium ions. CLF-PIP salt is easily reproducible 
compared to cytosinium salt and it exhibits the highest solubility of 18.3 mg/mL 
and two times improvements in dissolution rate of 0.98 mg/cm
2
/min with respect 
to the solubility 2.7 mg/mL and dissolution rate 0.42 mg/cm
2
/min of CLF drug in 
20% EtOH-water mixtures (Figure 6.5).     
  
 
 
(a) (b) 
Figure 6.4 (a) N
+–H···O– interactions between the piperazinium ion and CLF (b) 
two point N–H···O synthon between the neutral and ionic cytosine in CLF-CYT 
hydrate complex. 
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Figure 6.5 Dissolution profiles of CLF and CLF-PIP salts in 20% EtOH-water 
mixture at 37 ºC. 
CHAPTER SEVEN 
Conclusions and Future Prospects 
APIs can exist in different solid forms, such as polymorphs, 
pseudopolymorphs (solvates and hydrates), salts, co-crystals and amorphous 
solids. Almost 50% of all the APIs are shown to be polymorphic. Polymorphs are 
possible for each of these solid forms if money and time spend rigorously. Each 
form may possess its own unique mechanical, thermal, physical and chemical 
properties that can remarkably affect the solubility, bioavailability, 
hygroscopicity, melting point, stability, compressibility and other performance 
characteristics of the drug. A thorough understanding of the relationship between 
a particular solid form and its functional properties are crucial for selecting the 
most suitable form of the API for scale up, formulation activities, clinical trials, 
and finally manufacturing. This exercise requires inputs about crystallization, 
pharmacology and formulation. Hence several new polymorphs were identified 
and their phase transitions and stability order was established in chapter 2 for 
cardiosulfa and its similar molecules. Moreover, general relationship between 
molecular twist and higher solubility for aryl sulfonamides emerged from six 
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sulfonamide molecules. Planar sulfonamide molecules pack more efficiently in 
the crystal lattice and hence are less soluble; molecules with a bent molecular 
conformation were found to have higher solubility. Finally, Cardiosulfa appears 
to be the best candidate in the series studied because despite its lower solubility 
there is no evidence of polymorphs. In chapter 3, the structural-cum-solubility 
study of neutral and zwitterionic polymorphs of selected four ampholytes 
provides methods for their preparation and a comparison of solubility–stability 
characteristics. Generally solubility and stability are inversely related for drug 
polymorphs. We show that the twin characteristics of high solubility and good 
stability may be jointly optimized in the same zwitterionic polymorph for 
amphoteric drugs. The selective crystallization of zwitterionic forms could be 
possible through crystallization promoter additives such as ionic liquids, 
polymer-induced heteronucleation, and seeding with ionic structural mimics. In 
chapter 4, the stability of form II is compared with the weak interactions to 
understand the hydrogen bonding-crystal stability relationship. 
More than 80% drugs are marketed as solid formulations and 90% of 
them are crystalline in nature. Hence, pharmaceutical scientists constantly strive 
to improve physical properties of active pharmaceutical ingredients (APIs) using 
several formulation techniques such as cocrystal, salt formation and eutectic 
mixture preparation.  API is a substance (mostly solid crystal) that is 
pharmaceutically active in a drug and are delivered to the patients in the solid-
state as part of dosage forms (e.g. tablets, capsules, granules, powders, etc.) 
because of their easy uptake in the body. Much of the research is being focussed 
to improve the physical properties of API crystals using pharmaceutical 
cocrystallization/salt formation technique since the efficiency of the dosage form 
is often strongly related to API and the desired improvements in terms of 
crystallinity, solubility, hygroscopicity, stability, particle size, flow, filterability, 
density and taste can be often achieved by these methods. In chapter 4 and 5, a 
nitrate salt and three cocrystals of voriconazole with PHBA, PABA and 3-NBA, 
sodium-gliclazate, piperazinium-clonixate and cytosinium-clonixate were 
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prepared in bulk as well as by solution crystallization and therefore the solubility 
(10 times more soluble) and dissolution rates (3 times faster dissolving) of 
selected drugs voriconazole, gliclazide and clonixin were improved almost by the 
salt formation. Novel salts of clofibiric acid with piperazine and cytosine were 
also identified. Some of the cocrystals VZL-PABA etc. of voriconazole are more 
soluble (3 times) than the reference drug.  Identifying the optimum solid form of 
an active pharmaceutical ingredient (API) using cocrystallization/salt formation 
and solid solution/eutectic composition is a challenging task towards thickening 
the pipeline of high solubility drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
